Work

Phase I study of ABBV-399, a c-Met antibody-drug conjugate (ADC), as monotherapy and in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.2509

Authors: Eric Angevin, John H. Strickler, Colin D. Weekes, Rebecca Suk Heist, Daniel Morgensztern, John J. Nemunaitis, Xiaolin Fan, Juliette Beaulieu, Monica Motwani, Daniel E. Afar, Louie Naumovski, Karen Kelly

Institutions: Institut Gustave Roussy, Duke Medical Center, University of Colorado Denver, Massachusetts General Hospital, Washington University in St. Louis, Mary Crowley Cancer Research Center, AbbVie (United States), UC Davis Comprehensive Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2666875351

Cites:

Cited by: 6

Related to: 10